Fig. 6.

CTGF regulated by Egr-1 through ERK1/2 MAPK signaling in high glucose-induced VSMCs. Treatment with high glucose of 22.2 mM, Egr-1 protein expression (A, B), pretreatment with PD98059 (25 µM), U0126 (2.5 µM) (C), transfection with Egr-1 or control siRNA and recombinant CTGF treatment (D) were measured by western blot. Pretreatment with PD98059 (25 µM), U0126 (2.5 µM) and CTGF treatment in high glucose of 22.2 mM analyzed by MTT assay. Results are represented as the mean±S.E.M (n=4). ^*p<0.01 compared with 5.55 mM glucose, ^#p<0.01 compared with 22.2 mM glucose, ^$p<0.01 compared with 22.2 mM glucose plus MEK1/2 inhibitor.